Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2013
11/21/2013US20130309253 Cancer treatment with endothelin receptor antagonists
11/21/2013US20130309252 Antagonists of grasp55 for use as a medicament
11/21/2013US20130309249 Materials and methods for the prophylactic treatment of a pre-malignant condition
11/21/2013US20130309244 Methods and compositions combining immunotherapy with monocyte activation
11/21/2013US20130309243 Tam receptors and tam receptor ligands in detection and modulation of neuropathological disease
11/21/2013US20130309242 Purified antibody composition
11/21/2013US20130309241 Methods of Treating Vascular Disease using IL-1beta Antagonists
11/21/2013US20130309240 Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination
11/21/2013US20130309238 Signal transduction pathway modulation
11/21/2013US20130309236 Anti-interferon-alpha antibodies
11/21/2013US20130309234 Correlation of de novo-induced tumor-associated humoral immune responses with improved clinical outcome
11/21/2013US20130309232 Vascular endothelial growth factor 2
11/21/2013US20130309231 Methods for using taci-immunoglobulin fusion proteins
11/21/2013US20130309229 Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
11/21/2013US20130309227 Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
11/21/2013US20130309226 High-concentration monoclonal antibody formulations
11/21/2013US20130309225 Combination of cd37 antibodies with ice
11/21/2013US20130309224 Combination of cd37 antibodies with rituximab
11/21/2013US20130309222 Affinity peptides toward infliximab
11/21/2013US20130309194 Inhibition of il-17 production
11/21/2013US20130309193 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
11/21/2013US20130309191 Compounds for the treatment of clostridium difficile-associated disease
11/21/2013US20130309179 Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with porphyromonas gingivalis
11/21/2013US20130309173 Methods and compositions for maintenance of a functional wound
11/20/2013EP2664923A2 Biomarkers for central nervous system diseases
11/20/2013EP2664624A1 Allergen variants
11/20/2013EP2664346A1 Anti-sclerostin antibodies
11/20/2013EP2664345A2 Vaccine for inducing an improved immune reaction
11/20/2013EP2664344A1 Ehrlichia canis diva (differentiate infection from vaccinated animals)
11/20/2013EP2664340A2 A direct drug delivery system based on thermally responsive biopolymers
11/20/2013EP2664332A1 Vaccine composition containing synthetic adjuvant
11/20/2013EP2663580A1 Combination therapy including tumor associated antigen binding antibodies
11/20/2013EP2663579A2 Therapeutic antibodies against ror-1 protein and methods for use of same
11/20/2013EP2663334A2 Antibodies directed against influenza
11/20/2013EP2663333A2 Stem cell factor inhibitor
11/20/2013EP2663331A1 Novel uses
11/20/2013EP2663330A1 Anti-tlr4 antibodies and methods of use thereof
11/20/2013EP2663329A2 Tlr3 binding agents
11/20/2013EP2663328A1 Infectious hepatitis e virus genotype 3 recombinants
11/20/2013EP2663327A1 Compositions and methods for treating viral infections
11/20/2013EP2663318A1 Pharmaceutical composition for treating cancer
11/20/2013EP2435066B1 Assays for influenza virus hemagglutinins
11/20/2013EP2411047B1 Vaccine for protection against streptococcus suis bacteria of various serotypes
11/20/2013EP2364721B1 Vaccine compositions comprising a saponin adjuvant
11/20/2013EP2300609B1 Novel immunoadjuvant flagellin-based compounds and use thereof
11/20/2013EP2272869B1 Angiopoietin-2 specific binding agents
11/20/2013EP2205640B1 Antibodies that bind il-4 and/or il-13 and their uses
11/20/2013EP2203478B1 Compositions and methods for use of antibodies against sclerostin
11/20/2013EP2130921B1 Vaccine for prevention and treatment of HIV-infection
11/20/2013EP2077857B1 Immunisation method against the 4 dengue serotypes
11/20/2013EP2075334B1 EG-VEGF nucleic acids and polypeptides and methods of use
11/20/2013EP1841794B1 Adam-9 modulators
11/20/2013EP1809325B1 Vaccines against japanese encephalitis virus
11/20/2013EP1765396B1 Anti-psgl-1 antibodies
11/20/2013EP1518558B1 Vaccine against infection with Actinobacillus pleuropneumoniae comprising purified ApxIV toxin
11/20/2013CN1989250B Tc-83-derived alphavirus vectors, particles and methods
11/20/2013CN103402582A Methods of treating macular edema using anti-edema therapeutics
11/20/2013CN103402544A Conjugation process
11/20/2013CN103402542A Medicinal agent for inhibiting metastasis of malignant tumor
11/20/2013CN103402541A Enhancement of allogeneic hematopoietic stem cell transplantation
11/20/2013CN103402540A Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
11/20/2013CN103402539A A synthetic immunogen useful for generating long lasting immunity and protection against pathogens
11/20/2013CN103402538A Antibody drug conjugates (ADC) that bind to 191p4d12 proteins
11/20/2013CN103397000A Human diploid cell adapted strain of rabies virus and preparation method and application thereof
11/20/2013CN103396999A H9N2 subtype virus, H9N2 subtype virus vaccine and preparation method thereof
11/20/2013CN103396495A Fusion protein comprising Fc receptor binding polypeptide and antigenic polypeptide and used for mediateimmune response
11/20/2013CN103396492A Human platelet collagen receptor resistant human-derived monoclonal antibody fragment and application thereof
11/20/2013CN103396491A Monoclonal antibodies against human anti-mullerian hormone type II receptor (AMHR-II), and manufacturing method thereof and application
11/20/2013CN103396489A Engineered anti-IL-23p19 antibodies
11/20/2013CN103396487A Anti-IGF antibodies
11/20/2013CN103396485A Method and composition for targeting polyubiquitin
11/20/2013CN103396415A Novel substituted imidazoquinolines
11/20/2013CN103394108A Improved method for producing oocysts
11/20/2013CN103394097A Primers of transmissible gastroenteritis-porcine epidemic diarrhea combined vaccine and preparation method
11/20/2013CN103394096A Novel viral vector
11/20/2013CN103394084A Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs
11/20/2013CN103394083A Monomethylvaline compounds capable of conjugation to ligands
11/20/2013CN103394082A Multivalent immunogenic composition
11/20/2013CN103394081A Method for producing avian influenza vaccine by using WAVE bioreactor
11/20/2013CN103394080A Vaccination of young animals against lawsoniaintracellularis infections
11/20/2013CN103394079A Cancer vaccine composition
11/20/2013CN103393721A Preparation technology and medical applications of compound specific transfer factor
11/20/2013CN103393601A Microspheres comprising protein and showing injectability at high concentration of protein
11/20/2013CN102838680B Helicobacter pylori multiple-epitope fusion protein and multiple-epitope vaccine prepared by helicobacter pylori multiple-epitope fusion protein
11/20/2013CN102743750B Compound immunoenhancement agent, vaccine for birds and method for preparing compound immunoenhancement agent
11/20/2013CN102526751B Heat-resistant freeze-dried protective agent for swine fever spleen and lymph tissue origin live vaccine and preparation method for heat-resistant freeze-dried protective agent
11/20/2013CN102286102B Method for preparing sodium-potassium adenosine triphosphatase (ATP) DR domain specific antibody and medicinal effect thereof in treatment of kidney ischemia-reperfusion injury
11/20/2013CN101797382B Anti-human progastrin polypeptide immune composition
11/20/2013CN101646456B Methods and compositions for depleting specific cell populations from blood tissues
11/20/2013CN101616687B Non-specific immunostimulating agents
11/20/2013CN101460195B Methods for treating conditions associated with masp-2 dependent complement activation
11/19/2013US8586716 EPHB3-specific antibody and uses thereof
11/19/2013US8586714 Dual variable domain immunoglobulins and uses thereof
11/19/2013US8586712 Humanized antibodies
11/19/2013US8586555 Immunomodulatory compositions, formulations, and methods for use thereof
11/19/2013US8586538 Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
11/19/2013US8586531 Erythropoietin immunoglobulin fusion proteins
11/19/2013US8586528 Biologically active peptides and their new uses
11/19/2013US8586525 Biologically active peptides and their new uses
11/19/2013US8586364 Cells and methodology to generate non-segmented negative-strand RNA viruses
1 ... 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 ... 1823